Medications Development for the Treatment of Cannabis-Related Disorders (R21)

The summary for the Medications Development for the Treatment of Cannabis-Related Disorders (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Medications Development for the Treatment of Cannabis-Related Disorders (R21): Purpose: This funding opportunity announcement (FOA) solicits Exploratory/Developmental (R21) grant applications from applicant organizations that propose to conduct preclinical and clinical research directed towards the identification, evaluation and development of safe and effective medications for the treatment of Cannabis Related Disorders (CRDs) and their medical and psychiatric consequences. They include the Cannabis Use Disorders (CUDs) such cannabis abuse and dependence, the Cannabis Induced Disorders (CIDs) such as intoxication, psychosis, and anxiety, as well as the comorbidity of these disorders with other medical and psychiatric disorders (e.g., depression). Cannabis use includes marijuana, hashish, and other tetrahydrocannabinol (THC) containing substances. NIDA is encouraging research in this area because there is a high prevalence of marijuana use in the general population accompanied with an increasing misperception that its use poses low health risk, there is limited research in this area, and there are no effective pharmacological treatments available for these disorders. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-07-365, that solicits applications under the R01 mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Budget and Project Period: The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. Eligible Organizations: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organizations; Other(s): Eligible agencies of the Federal government; Faith-based or community based organizations. Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Application and Submission Information: Applicants may submit more than one application, provided each application is scientifically distinct. Application Materials. See Section IV.1 for application materials. Renewals and Resubmissions. Competing renewal (formerly competing continuation ) applications will not be accepted for the R21 mechanism. Up to two resubmissions (formerly revisions/amendments ) of a previously reviewed R21 grant application may be submitted.
Federal Grant Title: Medications Development for the Treatment of Cannabis-Related Disorders (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-07-366
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Apr 25, 2007
Creation Date: Apr 25, 2007
Archive Date: Dec 05, 2008
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) For profit organizations other than small businesses Small businesses Special district governments State governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Private institutions of higher education Independent school districts Public and State controlled institutions of higher education
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com